Pharmacokinetics of Orally Administered GS-441524 in Dogs.
Victoria C YanCong-Dat PhamMatthew J YanAlexander J YanSunada KhadkaKenisha ArthurJeffrey J AckroydDimitra K GeorgiouLaura E RoonLane R BushmanPeter L AndersonChun LiFlorian L MullerPublished in: bioRxiv : the preprint server for biology (2021)
Despite being FDA-approved for COVID-19, the clinical efficacy of remdesivir (Veklury ® ) remains contentious. We previously pointed out pharmacokinetic, pharmacodynamic and toxicology reasons for why its parent nucleoside GS-441524, is better suited for COVID-19 treatment. Here, we assess the oral bioavailability of GS-441524 in beagle dogs and show that plasma concentrations ∼24-fold higher than the EC 50 against SARS-CoV-2 are easily and safely sustained. These data support translation of GS-441524 as an oral agent for COVID-19.